The FDA completed a comprehensive review of the safety information relevant to the investigational small-molecule inhibitor of fatty acid amide hydrolase (FAAH) from Bial-Portela & Ca. SA, of Sao Mamede do Coronado, Portugal, linked to one death and five hospitalizations of volunteer subjects in a phase I trial at a France hospital early this year.